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Results: At 60 min, 850/2192 pts with AS >3 had an 11% greater absolute frequency of
complete STR (>70%) than 344/1239 with low AS (<3) p <0.001. Patients surviving to
discharge (fig.), showed that within each subgroup of STR, patients with high AS were
statistically more likely to have a small QRS infarct at discharge as compared to those
with low AS p<0.001. Moreover in a multivariate logistic regression model including base-
line characteristics, Σ ST, STR, time to treatment, the AS >3proved the strongest predic-
tor of small infarct size (OR=0.374, CI= 0.315-0.445).
Conclusion: Even after adjusting for time to treatment the AS provides novel insight into
the likelihood of STR 60 min after fibrinolysis and the probability of a smaller infarct size
regardless of the extent of STR. 
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Introduction: The therapeutic aPTT range of 50 to 70 sec recommended by the ACC/
AHA for patients receiving unfractionated heparin (UFH) for acute coronary syndromes
(ACS) is vulnerable to variation in test reagents. Rather than use the standard therapeu-
tic aPTT range, it has been recommended that each institution establish its own thera-
peutic aPTT range based upon anti-factor Xa levels. We evaluated our institution's
therapeutic aPTT range by examining the correlation between aPTTs and anti-factor Xa
levels and established a new therapeutic aPTT range with a new thromboplastin reagent
based upon the therapeutic anti-factor Xa levels.
Methods: 62 plasma samples were collected from 26 consecutive patients receiving
UFH for ACS. APTTs measured with a thromboplastin reagent and a new thromboplastin
reagent and anti-factor Xa levels were obtained on each plasma sample. Linear regres-
sion analysis was performed to establish a new therapeutic aPTT range from corre-
sponding therapeutic anti-factor Xa levels.
Results: 32% of patients with target range aPTTs had anti-factor Xa levels below the
accepted level of 0.35-0.7 U/mL for ACS while 68% had therapeutic anti-factor Xa levels.
When the same blood was tested with a new thromboplastin reagent, only 9% of patients
with target range aPTTs had anti-factor Xa levels <0.35 U/mL while 91% had therapeutic
anti-factor Xa levels. The Pearson correlation coefficient (r) for the new thromboplastin
reagent was 0.93. The slope of the regression line was 221.3. The therapeutic aPTT
range established with the new thromboplastin reagent was 61-100 sec.
Conclusion: Monitoring aPTTs without standardizing the thromboplastin reagent may
not adequately reflect therapeutic heparin levels. Despite apparently therapeutic aPTTs,
patients treated with UFH may be under-anticoagulated. Our new anti-Xa-adjusted thera-
peutic aPTT range shows an increase in the positive predictive value of aPTTs. Large-
scale clinical studies are needed to determine the optimal anti-factor Xa range for ACS
patients treated with UFH, with further refinements if GP IIb/IIIa antagonists are concom-
itantly used and to show a clinical benefit for monitoring heparin levels with anti-factor Xa
levels.
1117-91 Invasive Therapy Along With Glycoprotein IIb/IIIa 
Inhibitors and Intracoronary Stents Improves Survival in 
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Kenchaiah, Harvard School of Public Health, Boston, MA, Cleveland Clinic Foundation, 
Cleveland, OH
Background: Although several clinical trials have shown that early invasive therapy in UA/
NSTEMI patients reduces the risk of composite endpoints inclusive of death, MI or
angina, it is unclear whether such an approach improves survival.
Methods: We conducted a meta-analysis on five studies in a total of 6,766 UA/NSTEMI
patients who were randomized to either routine invasive (n=3,371) versus conservative
therapy (n=3,395) in the era of GP IIb/IIIa inhibitors and intra-coronary stents.
Results: As compared with conservative therapy, an invasive approach was associated
with a reduction in the risk of all-cause mortality at 6-12 months (3.3% vs. 4.2%, relative
risk [RR] 0.80, 95% confidence interval [CI] 0.63 to 1.03) and at 24 months (5.0% vs.
6.5%, RR 0.77, 95% CI 0.60 to 0.99) of follow-up. Although invasive therapy reduced the
risk of the composite endpoint of death or MI at 6-12 months in men (RR 0.68, 95% CI
0.57 to 0.81) and troponin positive patients (RR 0.74, 95% CI 0.59 to 0.94), the results for
women (RR=1.07, 0.82 to 1.41) and troponin negative patients (RR=0.82, 0.59 to 1.14)
were equivocal. 
Conclusions: Invasive therapy in UA/NSTEMI patients with adjunctive use of GP IIb/IIIa
inhibitors and intra-coronary stents improves survival. Enhanced risk stratification is
needed in women and troponin negative patients so that invasive therapy may be more
effectively recommended in these groups. 
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1118-77 Effects of Carvedilol Compared to Atenolol on Ejection 
Fraction and Clinical Endpoints After Myocardial 
Infarction
Gisli Jonsson, Michael Abdelnoor, Carl Müller, Sverre Erik Kjeldsen, Ingrid Os, Arne 
Westheim, Ullevaal University Hospital, Oslo, Norway
Background: Beta-blockers have been found to reduce mortality and morbidity in post-
myocardial infarction (MI) patients. However, it is not fully understood, whether all beta-
blockers have similiar favourable cardiovascular effects. The aim of this study was to
compare the effects of carvedilol and atenolol on global and regional ejection fraction
(EF), and on predefined cardiovascular endpoints.
Methods: In a randomized, prospective, open and endpoint-blinded single center study,
118 patients received carvedilol (mean dosage 36.2 + 15.1 mg) and 114 patients atenolol
(mean dosage 72.1 + 30.6 mg). No difference in baseline data, such as age, gender,
race, smoking, hypertension, dibetes mellitus or lipid lowering treatment, was observed.
There was no difference in baseline characteristics regarding infarct localization, reperfu-
sion therapy and acute treatment between the groups. Treatment with aspirin (96%), sta-
tin (98%), and ACE-inhibitors was equal in the 2 groups. The global and regional left
ventricular (LV) EF were evaluated with gated blood pool scintigraphy.
Results: In the carvedilol group 90 cardiovascular endpoints were observed compared
to 104 endpoints in the atenolol group, with a hazard ratio (RR) 0.84 with 95% confidence
interval (0.74-0.94) (p=0.002). This occured despite similar global LVEF was 55 + 11% at
baseline, 57 + 10% at 3 months and 57 + 10% at 12 months in the carvedilol group and
53 + 9%, 56 + 10% and 56 + 9% in the atenolol group respectively. No difference in
regional EF was observed in the two groups. The main contributor to the difference in
cardiovascular endpoints was a composite of cardiovascular deaths, non-fatal MI, and
congestive heart failure (worsening and hospitalization).
Conclusion: In patients following an acute MI, carvedilol treatment compared to atenolol
was associated with a significant reduction in combined cardiovascular endpoints despite
that no difference in global or regional ejection fractions was found. Thus other mecha-
nisms than remodelling might explain this difference in clinical effect between the two
drugs.
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Background: Combined reperfusion therapies widely applicable could benefit the still
high proportion of patients (pts) with ST-elevated acute myocardial infarction (STEAMI)
for whom primary PCI is not available due to logistic reasons.
Methods: We compared the evolution of 212 pts with STEAMI (<12 hs from onset) ran-
domised to 2 strategies: 1) primary PCI optimally performed (stenting of culprit artery
under protection of abcximab within 3 hs from onset); or 2) a combined (facilitated) strat-
egy: immediate thrombolysis (T) with tenecteplase (full bolus dose adjusted by weight)
